Search for: [Abstract = "Atrial fibrillation \(AF\) increases the risk of thromboembolism that is reduced by vitamin K antagonists \(VKAs\). Prothrombotic fibrin clot phenotype might be arisk factor for thromboembolic complications. Fibrin clot properties in patients taking VKAs have not been investigated yet. We evaluated an automated method for fibrin clot permeability \(Ks\) assessment, tested whether long\-term treatment with VKAs affects the structure of fibrin network, and investigated changes in plasma fibrin clot phenotype at the onset of oral anticoagulation. We showed that 10 pM TF as a coagulation trigger may reflect the in vivo process from initiation of the coagulation cascade to fibrin formation in AF patients taking VKAs. Finally, we demonstrated that plasma fibrin clot properties in AF patients are favourably modified as early as after 3 days of VKA administration, which might contribute to anticoagulant and antithrombotic effectiveness."]

Number of results: 1